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INTRODUCTION	For	the	improvement	of	the	delivery	of	new	DNA	into	the	cell,	the	DNA	must	be	protected	from	its	damage	and	its	entry	into	the	cell	must	be	done	properly.	The	new	molecules,	lipoplexes,	have	been	originated	that	have	 the	 ability	 to	 save	 the	 DNA	 from	 undesirable	degradation	during	 the	 transfection.	Cationic	 lipids,	because	 of	 their	 positive	 charge,	 form	 natural	complex	with	the	negatively	charged	DNA.	Also	as	a	result	 of	 their	 charge	 they	 interact	 with	 the	 cell	
membrane,	endocytosis	of	the	lipoplex	occurs	and	the	DNA	 is	 released	 into	 the	 cytoplasm.	 The	 cationic	lipids	also	act	as	a	 saver	against	degradation	of	 the	DNA	by	the	cell.	Cationic	 lipids	are	 the	 lipids	which	are	amphiphilic	in	nature.[1]	A	huge	amount	of	work	has	been	done	for	the	benefit	of	novel	formulations	of	cationic	liposomes,	through	the	formation	of	various	cationic	lipids	with	less	toxic	substances	and	having	various	possibilities	to	mediate	gene	movement.[2]	Besides	 DOTMA	 (2,3-bis(oleoyl)oxipropyltri-methylammoniumchloride)	 andDOTAP(N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammoniumme-thyl-sulfate)	are	the	two	most	famous	cationic	lipids,	whose	 acyl	 chains	 are	 linked	 to	 the	 propyl	 ammo-nium	group,various	new	lipids	have	become	available	for	 transfection	 purposes.[2]	 Cationic	 lipid	 or	 lipo-plexes	 have	 been	 the	 subject	 of	 inquiry	 in	 recent	years	to	understand	the	parameters	governing	the	ef-ficiency	of	transfection.	Cationic	lipids	are	sometimes	used	 in	 combination	 with	 helper	 lipids	 such	 as	DOPE(dioleoylphosphatidylethanolamine)	 or	cholesterol.	[3]	Cationic	 lipid-mediated	gene	transfer	is	mainly	used	 for	 their	 advantages	 over	 viral	 gene	transfer	 because	 it	 is	 non-immunogenic,	 easy	 to	produce	and	they	are	not	oncogenic.	The	main	draw-back	of	the	application	of	cationic	lipids	is	their	low	transfection	efficiency.	 [4]	The	main	knowledge	 is	of	the	structure-activity	relationships	of	lipoplexes	and	of	the	mechanisms	involved	in	the	process	of	intracel-lular	 gene	delivery	 is	 short.	 It	 is	 believed	 that	 such	
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type	of	knowledge	is	crucial	to	improve	the	biological	activity	 of	 these	 systems	 and	 therefore	 gaining	perception	into	these	mechanical	aspects	should	con-stitute	one	of	the	main	goals	in	this	field.	Since	1987,	when	a	cationic	lipid	was	reported	for	the	use	to	for-mulate	the	first	vesicle	used	for	introduction	of	plas-mid	DNA	(pDNA)	into	cells.[5]	Cationic	liposomes	can	combine	DNA	 into	a	 cationic	particle	when	 the	 two	components	 are	 mixed	 together.	 This	 cationic	 li-pid/DNA	complex	(lipoplex)	can	save	DNA	from	en-zymatic	degradation	and	deliver	the	DNA	into	cells	by	involving	with	the	negatively	charged	cell	membrane.	Lipoplexes	are	not	an	ordered	DNA	phase	that	is	been	enclosed	 by	 a	 lipid	 bilayer	 and	 they	 are	 a	 partially	concised	DNA	complex	with	an	instructed	substruc-ture	and	with	an	asymmetrical	morphology.[6]	All	 cationic	 molecule	 based	 systems	 have	 been	disappointed	or	they	have	not	been	good	to	influence	the	clinical	trials	due	to	their	low	gene	transfer	effi-cacy	and	toxicity	of	substances	associated	with	infec-tion.	Although	the	beginning	of	toxicity	is	not	fully	un-derstood,	a	combination	of	unmethylated	nucleic	ac-ids	and	the	cationic	molecules	and	maybe	the	larger	diameter	of	the	lipoplexes,	play	a	major	role	in	the	in-auguration	of	the	toxicity.[7]	Although	the	majority	of	clinical	trials	have	been	based	on	the	use	of	viral	vec-tors	 cationic	 liposomes	 are	 appearing	 as	 promising	non-viral	carriers	for	genetic	medicines	due	to	their	safety	and	versatility.[8]	Lipoplexes	likely	enter	cells	mainly	by	adsorptive	en-docytosis.[9]	The	 intracellular	 route	 is	not	yet	clear-cut;	but,	it	is	fair	that	only	a	small	fraction	of	the	lipo-plexes	is	able	to	avoid	lysosomal	degradation	and	to	finish	up	in	the	nucleus.[10]	The	transfection	capacity	of	 lipoplexes	 in	vitro	depends	on	many	 framework,	such	as	their	physicochemical	characteristics,	type	of	cells,	 and	 incubation	 conditions.[11]	 However,	 of	 all	the	 currently	 available	 relevant	 information,	 the	logical	way	to	boost	lipofection	in	vivo	is	still	not	clear.	
From	cationic	liposomes	to	lipoplexes	As	many	attempts	had	been	made	to	use	standard	lip-osomes	for	gene	transportation,	the	little	skillfulness	of	 plasmid–DNA	 condition	 and	 therefore	 the	 low	plane	of	 transfection	pleased	 researcher	 to	develop	other	liposome-based	scheme.[12]	As	Behr[13]	demon-strated	 that	 cationic	 liposomes,	 could	 complex	 and	condense	DNA,	Felgner	 and	 collaborators	proposed	the	use	of	cationic	liposomes	as	economical	transport	for	the	intracellular	transportation	of	DNA.[14]	These	authors	prepared	liposomes	composed	of	the	cationic	lipid	 2,3-bis(oleoyl)oxipropyl	 trimethylammonium	chloride	 (DOTMA)	and	dioleoylphosphatidylethano-lamine	 (DOPE),	which	became	commercially	availa-ble	 as	 a	 transfection	 reagent	 designated	 lipofectin.	The	ability	of	this	system	to	mediate	transfection	was	attributed	 to	 recognition	 of	 certain	 properties,	namely:	 (1)	 a	 spontaneous	 electrostatic	 interaction	
between	 the	 positively	 charged	 liposomes	 and	 the	negatively	charged	DNA,	which	results	in	an	efficient	condensation	of	the	nucleic	acids;	(2)	the	fact	that	the	resulting	cationic	liposome/DNA	complexes	could	ex-hibit	a	net	positive	charge	that	promotes	their	associ-ation	with	the	negatively	charged	cell	surface	and	(3)	the	fusogenic	properties	exhibited	by	the	cationic	lip-osome	formulation	that	can	induce	fusion	and	desta-bilization	of	 the	plasma	membrane,	 thus	 facilitating	the	intracellular	release	of	complexed	DNA.	These	as-sumptions	sealed	the	way	to	pursue	studies	aiming	at	improving	the	biological	activity	of	lipoplexes,	which	allowed	the	identification	of	several	critical	parame-ters	that	affect	their	efficacy.	
Liposome	composition		
Cationic	lipids	Over	 the	 past	 some	 years	 a	 huge	 sum	 of	work	 has	been	done	for	the	improvement	of	novel	formulations	of	cationic	liposomes,	that	is	to	say	through	the	anal-ysis	 of	 various	 cationic	 lipids	with	 low	 toxicity	 and	showing	 various	 quality	 to	 mediate	 gene	 move-ment.[15]	DOSPA	and	DOGS,	which	are	ambiguous	cat-ionic	 lipids,	 signifies	 micellar	 instead	 of	 vesicular	structures	 and	 display	 a	 high	 effectiveness	 in	 com-pressing	DNA	than	univalent	lipids.	This	place,	how-ever,	does	not	surely	evidence	to	a	high	transfection	ratio,	since	the	intracellular	separation	of	DNA	from	the	compound	is	suppose	to	be	much	more	than	chal-lenging.[16]	In	general,	the	transfection	activity	of	cat-ionic	 lipids	 decreases	 with	 increasing	 alkyl	 chain	length	 and	 saturation.	 Shorter	 alkyl	 chain	 length	approves	higher	rates	of	intermembrane	transfer	of	lipid	monomers	and	lipid	membrane	mixing.	A	non-stop	connection	betwixt	the	universe	of	the	tied	unit	of	cationic	lipids	and	their	possible	toxicity	was	also	revealed.	Lipids	with	constant	ether	attachment	are	more	 than	 poisonous	 than	 those	 including	 reactive	ester	attachment.	
Co-lipids	The	value	of	associating	a	co-lipid	to	finer	the	quality	of	 cationic	 lipids	 to	 transfer	 cells	 has	 been	 demon-strated.	In	vitro	survey	clearly	display	that	liposomes	combined	of	an	equimolar	mixture	of	DOPE	and	cati-onic	lipids	can	intermediate	at	high	plane	of	transfec-tion	than	those	including	only	the	cationic	lipid	or	a	different	 supporter	 lipid	 like	 DOPC.[17]	 This	 infor-mation	has	been	assigned	to	the	quality	of	DOPE	to	facilitate	 the	 formation	 of	 liposomes	 in	 conjuction	with	 cationic	 lipids	 and	 to	 its	 inclination	 to	 go	through	a	conversion	from	a	bilayer	to	an	hexangular	conformation	below	acidic	pH,	which	may	serve	mer-ger	with	or	modification	of	victim	tissue	layer,	in	par-ticular	endosomal	tissue	layer.[18]	More	recently,	it	has	been	recommended	that	DOPE	can	also	show	a	role	in	assisting	the	set	up	of	the	lipid	based	 DNA	 formulations	 later	 their	 incorporation	
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and	escapism	of	DNA	from	endocytotic	cyst.[19]	Cho-lesterol	has	also	been	hired	as	a	co-lipid	to	prepare	cationic	liposomes,	resulting	in	the	formation	of	more	lasting	 but	 less	 efficient	 complexes	 than	 those	 con-taining	 DOPE.	 In	 contrast,	 cholesterol-containing	complexes	 have	 showed	 the	 high	 natural	 activity	compared	to	complexes	with	DOPE	when	these	com-plexes	were	used	in	vivo.[20]	
Structure	and	size	of	cationic	liposomes	The	way	by	which	the	structure	and	size	of	cationic	liposomes	 to	 transfect	 cationic	 liposomes	 affect	 the	physico-chemical	properties	and	biological	activity	of	the	lipoplexes	is	an	important	issue	that	needs	to	be	clarified.	In	the	great	bulk	of	transfection	studies	lip-oplexes	are	processed	from	large	unilamellar	cationic	liposomes	(LUVs),	possessing	sizes	close	to	100	nm,	and	from	small	unilamellar	cationic	liposomes	(SUVs)	with	 sizes	 ranging	 between	 20	 and	 100	 nm.	 It	 has	been	demonstrated	that	for	a	given	liposome	mixture,	multilamellar	 liposomes	 (MLVs),	 which	 usually	 ex-hibit	 an	 average	 size	 ranging	 from	 400	 to	 800	 nm,	when	complexed	with	DNA	intermediate	high	trans-fection	 activity	 than	 compound	 prepared	 from	SUVs.[21]	 However,	 a	 novel	 method	 to	 modify	 the	properties	of	lipid–DNA	complexes	was	recently	pro-posed,	consisting	of	both	bulge	of	the	liposomes	(to	obtain	 large	 unilamellar	 liposomes,	 LUVs)	 and	 con-tained	mixing	of	 lipid	and	DNA.	This	procedure	has	been	 shown	 to	 result	 in	 lipoplexes	 showing	 small	sizes	within	a	constricting	distribution	that	present	a	high	colloidal	stability	and	equal	to	features	for	their	
in	 vivo	 use.[22]	 Recently,	 it	 was	 rumored	 that	 lipo-plexes	 resulting	 from	 MLVs	 do	 not	 disagree	 im-portantly	 in	 their	magnitude	or	 in	 the	 level	of	 their	cell	 organisation	 and	 consumption.	 Similarly,	 the	transfection	activity	mediated	by	the	resultant	com-plexes	was	observed	to	be	dependent	on	the	final	size	of	 the	 complexes	 and	 not	 on	 the	 type	 of	 liposomes	used.[23]	Although	recent	models	proposed	for	the	of	the	lipo-plexes,	which	 identify	 them	as	multilamellar	 aggre-gates,	were	settled	on	studies	using	SUVs,	recent	find-ings	 declared	 that	 in	 the	 process	 of	 lipoplex	 for-mation,	DNA	induces	the	generation	of	multilamellar	liposomes	 from	 unilamellar	 vesicles.[24]	 Thus,	 the	outcome	of	using	MLVs	instead	of	SUVs	on	the	final	properties	 of	 the	 complexes	 remains	 to	 be	 clari-fied.[25]	 The	 apparent	 discrepancy	 of	 results	 rein-forces	the	need	of	further	research	focused	on	the	un-derstanding	and	control	of	pharmaceutical	variables	involved	in	the	preparation	of	the	cationic	lipid-based	gene	delivery	systems.[26]	
Mode	of	lipoplex	formation	It	 is	well	 recognized	 that	 the	mode	 of	 formation	 of	complexes	 strongly	 determines	 the	 final	 physico-chemical	features	of	the	lipoplexes	and,	consequently,	modulates	their	biological	activity.[27]	In	the	last	few	
years	a	significant	effort	has	been	devoted	to	gain	in-sights	 into	 the	parameters	 that	affect	 the	 formation	and	the	resulting	structure	and	morphology	of	the	lip-oplexes.[28]	Both	experimental	and	theoretical	studies	have	been	performed	and	different	models	have	been	proposed	for	the	cationic	lipid–DNA	complexes.[29]	
	
Figure	1:	Composition	of	some	cationic	lipids	
usually	used	in	gene	therapy	Initially,	 based	 on	 light	 scattering	 results	 that	 indi-cated	 a	 slight	 size	 increase	 of	 the	 lipoplexes	 com-pared	to	the	cationic	liposomes,	the	calculation	of	the	number	of	positive	charges	per	liposome,	as	well	as	the	possibility	of	complete	charge	neutralization	for	lipoplex	 formation,	 it	 was	 proposed	 that	 the	 lipo-plexes	 resulted	 from	 the	 constricting	 of	 four	 entire	cationic	liposomes	to	the	plasmid–DNA	strand	medi-ated	by	electrostatic	interactions.[30]	Gershon	and	col-laborators,[31]	 by	 using	 electron	 microscopy,	 pro-posed	a	different	model	for	the	formation	of	the	com-plexes	 according	 to	which,	 at	 low	 lipid	 /DNA	 (+/-)	charge	ratios,	cationic	liposomes	are	adsorbed	at	the	surface	 of	 DNA	 molecules	 forming	 aggregates	 that	progressively	surround	large	segments	of	DNA.	The	continuous	addition	of	liposomes	to	a	critical	concen-tration	 and	 density	 results	 in	 DNA-induced	 mem-brane	 fusion	 and	 liposome	mediated	 DNA	 collapse	and	condensation.	According	to	these	authors,	these	processes	result	in	coating	of	DNA	with	a	cationic	li-pid	bilayer	along	the	full	length	of	the	plasmid.	
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Similar	 observations	 were	 also	 made	 by	 Sternberg	and	collaborators	who,	using	freeze	fracture	electron	microscopy,	 described	 the	 morphology	 of	 the	 lipo-plexes	 as	 aggregates	 of	 cationic	 liposomes	 encom-passing	DNA	molecules	(designated	 ‘bead	on	string’	arrangements)	 that	 coexist	 with	 tubular	 structures	composed	of	DNA	molecules	coated	by	lipid	bilayers.	This	 gave	 rise	 to	 the	 so-called	 ‘spaghetti-meatballs’	model.[32]	More	recently,	an	important	breakthrough	towards	 understanding	 the	 interactions	 between	DNA	and	cationic	liposomes	as	well	as	the	structure	of	the	resulting	lipid	/DNA	complexes	was	provided	by	a	combined	 in	 situ	 optical	microscopy	and	X-ray	diffraction	 approach.	 The	 mixture	 of	 cationic	 lipo-somes	 with	 DNA	 results	 in	 a	 topological	 transition	from	 the	 liposomal	 structure	 to	 a	 liquid-crystalline,	concentrate	and	round	construction,	position	of	DNA	mono	 layers,	 defined	 by	 a	 consistent	 inter-helical	spacing,	which	are	prepared	betwixt	cationic	lipid	bi-layers.	This	 structure	was	designated	 the	Lάc	struc-ture.[33]	More	recently,	 the	role	of	DOPE	 in	 the	 lipoplex	 for-mation	was	 far	 investigated	 by	 performing	 circular	dichroism	measurements.	These	studies	showed	that	the	 involvement	 of	 DOPE	 in	 cationic	 liposomes	causes,	 in	 addition	 to	 secondary	 conformational	changes	observed	for	pure	DOTAP	liposomes,	a	ter-tiary	DNA	transition	that	results	from	the	embedding	of	DNA	within	the	lipid	columnar	inverted	-hexagonal	assembly,	 which	 in	 turn	 provides	 the	 DNA	 with	 a	given	spatial	organization	and	fixed	directionality.[34]	The	authors	proposed	that	this	DNA	packaging	mode	is	 interconnected	and	co-exists	with	short	unbound	segments	of	DNA	which	appear	along	the	hexagonal	assembly	and	meet	 into	a	highly	 condensed	bundle	characterized	 by	 a	 left	 handed	 chirality.[35]	 Overall,	these	findings	contribute	to	rationalize	the	choice	of	the	‘helper’	lipid	in	the	cationic	liposomes.	Another	interesting	contribution	to	the	understand-ing	 of	 the	 mode	 of	 lipoplex	 formation	 was	 re-ported.[33,34]	 Based	 on	 experimental	 evidence	 pro-vided	by	cryo-electron	microscopy	and	light	scatter-ing	 analysis,	 these	 authors	 described	 a	 novel	 mor-phology	 for	 cationic	 liposome–DNA	complexes	 con-sisting	 of	 condensed	 DNA	 in	 the	 interior	 of	illuminated	liposomes	between	two	lipid	bilayers.	As	described	above,	these	authors	also	found	that	the	fi-nal	structure	of	the	lipoplexes	is	dependent	on	the	lip-osome	 composition.	 Despite	 the	 various	morpholo-gies	for	the	lipoplexes	presented	in	the	literature	and	summarized	above,	it	is	not	yet	possible	to	accurately	define	which	are	 the	 conditions	or	 factors	 that	 find	out	each	of	them.	In	fact,	it	is	reasonable	not	to	take	out	the	possibility	that	the	different	structures	co-ex-ist	in	the	same	preparation	and	that	the	observed	dif-ferences	can	be	attributed	to	the	lack	of	control	of	the	different	variables	involved	in	the	complex	prepara-tion,	 as	well	 as	 to	 the	 fact	 that	different	 techniques	
have	been	utilized	to	study	lipid	bilayers	and	thus	to	evaluate	lipoplex	morphology.[36]	Evidence	 in	 support	of	 this	hypothesis	has	 recently	been	reported	by	Fang	and	Yang	who	have	directly	representated	 DNA	 on	 lipid	 membranes	 by	 atomic	force	microscopy	(AFM),	 showing	clear-cut	ordered	domains.	
Parameters	 affecting	 the	 physico-chemical	
properties	of	lipoplexes	The	physico-chemical	 characteristics	 including	 size,	charge	 density	 and	 colloidal	 stability	 are	 relevant	properties	of	lipoplexes	that	determine	their	success-ful	 use	 both	 in	 vitro	 and	 in	 vivo.	 Therefore,	 under-standing	the	parameters	that	modulate	such	proper-ties	is	of	crucial	importance.	Like	in	other	systems,	the	physico-chemical	proper-ties	 of	 the	 lipoplexes	 depend	 on	 several	 thermody-namic	 as	well	 as	 kinetic	 factors	 that	 affect	 complex	formation,	which	 therefore	should	be	considered	 in	their	 preparation.	 In	 this	 context,	 although	 several	questions	still	remain	to	be	clarified,	it	is	well	known	that	the	concentrations	of	cationic	lipid	and	DNA,	the	ionic	 strength	 and	 temperature	 of	 the	 suspending	medium,	the	order	of	addition,	the	mixing	rate	of	the	components,	 and	 the	 extent	 of	 complex	 formation	represent	critical	parameters.[37]	The	relative	proportion	of	cationic	lipid	and	DNA	de-termines	 the	 properties	 of	 the	 lipoplexes,	 namely	size,	surface	charge	(zeta	potential),	efficacy	of	com-plexation,	 colloidal	 stability	 and	 biological	 activity.	Recent	 studies	 have	 shown	 that	 highly	 positively	charged	complexes,	 in	which	DNA	 is	completely	se-questered	 and	 condensed,	 exhibit	 an	 homogeneous	size	 distribution	 (mean	 diameter	 between	 100	 and	450	nm).	A	similar	size	distribution	is	also	observed	when	complexes	are	prepared	with	an	excess	of	DNA	over	 cationic	 lipids	 (i.e.	 negatively	 charged	 com-plexes),	 although	 in	 this	 case	 the	 presence	 of	 free	DNA	 is	 generally	 observed.[38]	 On	 the	 other	 hand,	complexes	prepared	from	a	 lipid	/DNA	charge	ratio	of	approximately	1/1	exhibit	a	neutral	zeta	potential,	suggesting	 that	 all	 the	 cationic	 lipid	 molecules	 are	neutralized	by	DNA.	Such	neutral	complexes	are	char-acterized	by	a	heterogenous	size	distribution	(mean	diameter	from	350	to	1200	nm)	and	usually	present	a	much	lower	colloidal	stability	than	those	exhibiting	an	excess	of	net	positive	or	negative	charge.	This	can	be	attributed	to	a	lack	of	electrostatic	repulsive	forces	among	the	complexes	that	would	prevent	their	aggre-gation.[39]	
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The	 influence	 of	 lipid	 /DNA	 stoichiometry	 on	 the	physico-chemical	 properties	 of	 the	 complexes	 be-comes	 even	 more	 difficult	 to	 evaluate	 considering	that,	for	a	fixed	lipid	/DNA	charge	ratio,	the	increase	in	concentration	of	lipid	and	DNA	results	in	a	signifi-cant	change	of	their	size	and	colloidal	stability,	which	can	be	attributed	to	enhanced	precipitation	at	higher	concentrations	 due	 to	 smaller	 interparticle	 separa-tion.[40]	Since	thermodynamic	parameters	have	been	recognized	 to	 be	 involved	 in	 the	 formation	 of	 lipo-plexes,	the	DLVO	theory	has	been	applied	to	under-stand	how	different	parameters	affect	the	final	prop-erties	of	 lipoplexes.[41]	 In	this	regard,	 lipoplexes	are	usually	prepared	in	low	ionic	strength	solutions	in	or-der	to	decrease	precipitation.	Curiously,	the	precipi-tation	effect	caused	by	high	ionic	strength	is	particu-larly	 more	 pronounced	 during	 complex	 formation	than	in	the	stability	of	pre-formed	lipoplexes,	despite	the	the	fact	that	under	the	same	conditions	they	still	obey	the	DLVO	theory.	At	 low	 ionic	 strength,	 the	 attractive	 electrostatic	forces	required	for	lipoplex	formation	are	enhanced,	thus	leading	to	a	faster	and	more	intense	interaction	between	DNA	and	cationic	liposomes,	which	seems	to	prevent	 the	 aggregation	 and	 sedimentation	 of	 the	complexes.	 Temperature	 has	 been	described	not	 to	be	a	critical	parameter	affecting	lipid–DNA	complex	formation	as	well	as	their	final	properties,	as	long	as	DNA	denaturation	is	avoided.	Regarding	the	effect	of	kinetic	parameters,	it	 is	well	established	that	rapid	mixing	of	components	results	in	small	lipoplexes,	while	a	very	slow	mixing	often	re-sults	in	precipitation.[42]	By	analogy	to	crystal	growth,	
this	can	be	explained	by	the	slow	growth	of	a	few	nu-cleation	embryos	and	critical	 ratios	on	a	 local	 scale	that	favour	aggregation.	In	an	attempt	to	prevent	the	formation	 of	 neutral	 lipoplexes	 that	 tend	 to	 aggre-gate,	 empirical	 rules	 have	 been	 followed	 regarding	the	 order	 of	 addition	 of	 the	 lipid	 and	DNA.	 If	 posi-tively	charged	complexes	are	desired,	DNA	should	be	added	to	a	cationic	liposome	suspension.	The	inverse	will	be	true	to	obtain	negatively	charged	complexes.	
Production	of	liposomes	for	gene	delivery	Based	 on	 the	 content	with	 liposomal	 drug	 delivery	systems,	 it	 is	visualized	that	the	ideal	 liposomes	for	systemic	gene	delivery	will	enclose	plasmid	DNA	with	high	efficiencies,	will	protect	the	DNA	from	degrada-tion	by	plasma	nucleases,	will	have	a	thin	size	distri-bution,	averaging	100	nm	or	less	in	diameter,	in	order	that	the	liposomes	can	access	extravascular	regions,	and	will	have	the	potency	to	incorporate	a	wide	range	of	 lipids,	 that	 promote	 fusion	 with	 cellular	 mem-branes	 and/or	 enhance	 liposome	 constancy	 in	 the	circulation.	The	 feasibleness	 of	 passively	 encapsulating	DNA	 in	liposomes	was	demonstrated	in	the	late	1970s	using	a	number	of	the	methods	indicated.	For	example,	high	molecular	weight	DNA	 is	 trapped	 in	egg	phosphati-dylcholine	liposomes	by	hydrating	the	lipid	film	in	the	presence	 of	 DNA.[43]	 Reversed-phase	 evaporation	procedures	have	also	been	employed	to	enclose	plas-mid	DNAs	with	good	but	variable	encapsulation	effi-ciencies.	More	 recently,	 freeze	 drying	 methods	 have	 pro-ceeded	 DNA-containing	 multilamellar	 vesicles	 with	
Table 1: Marketed Products Sno.	 Clinical	products	 Approval	year	 Administration	 Active	agent	 Company	 References	
1.	 Doxil®	 1995	 I.V.	 Doxorubicin	 Sequus	Pharmaceuticals	 [44]	
2.	 DaunoXome®	 1996	 I.V.	 Doxorubicin	 NeXstar	Pharmaceuticals	 [45]	
3.	 Depocyt®	 1999	 Spinal	 Cytarabine/Ara-c	 Sky	Pharma	Inc.	 [46]	
4.	 Myocet®	 2000	 I.V.	 Doxorubicin	 Elan	Pharmaceuticals	 [45]	
5.	 Mepact®	 2004	 I.V	 Mifamurtide	 Takeda	Pharmaceuticals	Limited	 [47]	
6.	 Marqibo®	 2012	 I.V	 Vincristine	 Talon	Therapeutics	Inc.	 [47]	7.	 OnivydeTM	 2015	 I.V	 Irinotecan	 Merrimack	Pharmaceuticals	Inc.	 [48]	8.	 Abelcet®	 1995	 I.V	 Amphotericin	B	 Sigma	Tau	Pharmaceuticals	 [44]	9.	 Ambisome®	 1997	 I.V	 Amphotericin	B	 Astellas	Pharma	 [46]	10.	 Amphotec®	 1996	 I.V	 Amphotericin	B	 Ben	Venue	Laboratories	Inc.	 [46]	
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encapsulation	 efficiencies	 of	 50–60%.[44]	 For	 the	most	part,	however,	these	operations	yield	relatively	large	multilamellar	vesicles	with	 low	DNA	encapsu-lating	efficiencies	and	generally	low	gene	transfer	ca-pabilities.	 Extrusion	 of	 the	DNA	 containing	multila-mellar	vesicles	to	cut	down	the	particle	size	have	re-sulted	 in	 poor	 recoveries	 of	 DNA	 containing	 lipo-somes.	In	 the	 late	1980s,	 it	was	 shown	 that	 cationic	 lipids,	when	merged	in	dioleoylphosphatidyl-	ethanolamine	(DOPE)-containing	 liposomes,	 could	 raise	 the	 effi-ciency	of	gene	delivery	to	cultured	cells	in	vitro	by	(i)	increasing	the	organization	of	plasmid	DNA	with	lip-osomes	and	(ii)	increasing	the	constricting	of	cationic	liposome–plasmid	DNA	complexes	 to	cells.	This	has	prompted	many	researchers	to	analyze	different	cat-ionic	lipids	that	possess	improved	gene	transfer	and	cell	tolerability	properties,	as	well	as	to	develop	novel	procedures	 to	 efficiently	 encapsulate	 plasmid	 DNA	drug	inside	lipid-based	carriers.	
Some	properties	of	lipoplexes	They	 are	 non-immunogenic.	 They	 protect	 genetic	material	 from	 being	 degraded	 as	 they	 are	 cationic	they	easily	form	complexes	with	negatively	charged	genetic	 material.	 The	 disruption	 of	 the	 endosomal	membrane	 encouraging	 the	 endosomal	 escape	 is	done	by	the	lipoplexes.	They	communicate	with	cell	membrane	that	clear	the	way	for	the	endocytosis.[49]	They	 are	 difficult	 to	 produce	 as	 compared	 to	 other	complexes.	They	are	more	toxic	as	compared	to	other	lipids.	They	become	inactive	in	the	presence	of	serum.	They	 have	 lower	 transfection	 efficiency	 compared	with	viral	vectors.	
Applications	
• Lipoplexes	 are	 usually	 prepared	 in	 low	 ionic	strength	 solutions	 in	 order	 to	 decrease	precipitation.	
• The	most	common	use	of	lipoplexes	has	been	in	gene	 delivery	 into	 cancer	 cells,	 where	 the	supplied	genes	have	activated	tumor	suppressor	control	genes	in	cell	and	decrease	the	activity	of	oncogenes.	
• Recent	studies	shows	 that	 lipoplexes	are	useful	in	 transfecting	 respiratory	 epithelial	 cells,	 so	they	 may	 be	 used	 for	 treatment	 of	 genetic	respiratory	diseases	such	as	cystic	fibrosis.	
• Most	of	the	applications	are	based	on	the	various	types	of	gene	delivery	of	the	lipoplexes	and	their	compounds	 that	 are	 been	 used	 for	 the	 drug	delivery.	
• They	 are	 mainly	 based	 on	 the	 type	 of	 various	compounds	used	for	the	delivery	of	genes.	[49]		
	
	
Production	 of	 lipoplexes	 for	 conventional	 drug	
delivery	The	major	progression	in	lipoplex	technology	in	the	past	 has	 originate	 from	 the	 ability	 to	 produce	well	defined	 liposomes	 composed	 of	 a	 broad	 variety	 of	lipids	with	various	physical	and	chemical	properties.	Another	significant	advancement	has	come	from	the	ability	 to	 entrap	 drugs	 in	 liposomes	 with	 high	efficiency.	 Hydrophobic	 drugs	 can	 be	 directly	incorporated	 into	 liposomes	 during	 vesicle	formation.	Trapping	efficiencies	of	all	drugs	are	often	achievable,	but	are	dependent	on	the	solubility	of	the	drug	in	the	liposome	membrane.[47,48]		
CONCLUSION	Although	over	the	last	few	years	it	has	been	difficult	to	demonstrate	 the	synthesis	of	 lipoplexes	with	 the	help	 of	 cationic	 lipids.	 This	 review	 describes	 the	various	 cationic	 lipids	 that	 are	 used	 for	 the	 gene	delivery.	 It	 focuses	 on	 the	 various	 aspects	with	 the	effect	of	 liposome	composition	and	with	helper	and	co-lipids.	 It	 also	 describes	 structure	 and	 size	 of	cationic	 liposomes	 with	 the	 mode	 of	 lipoplex	formation.	It	also	briefly	describes	about	the	various	parameters	 that	 affects	 the	 physico-chemical	properties	 of	 lipoplexes.	As	 stated	 above,to	 achieve	such	a	goal,	attempts	have	been	made	to	present	viral	attributes	to	lipoplexes.		
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